Open AccessA comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency
Author(s) -
Nicolas Pallet,
Salma Hamdane,
Simon Garinet,
Hélène Blons,
Aziz Zaanan,
Éléna Paillaud,
Julien Taı̈eb,
Olivier Laprévôte,
M.A. Loriot,
Céline Narjoz
Publication year - 2020
Publication title -
british journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.833
H-Index - 236
eISSN - 1532-1827
pISSN - 0007-0920
DOI - 10.1038/s41416-020-0962-z
Subject(s) - dpyd , dihydropyrimidine dehydrogenase , medicine , genotype , oncology , gastroenterology , population , fluorouracil , exon , uracil , cancer , pharmacogenetics , genetics , biology , gene , thymidylate synthase , environmental health , dna
Pretherapeutic screening for dihydropyrimidine dehydrogenase (DPD) deficiency is recommended or required prior to the administration of fluoropyrimidine-based chemotherapy. However, the best strategy to identify DPD-deficient patients remains elusive.